SillaJen, Inc. (KOSDAQ:215600)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,755.00
+5.00 (0.13%)
Apr 10, 2026, 3:30 PM KST
Market Cap517.99B +54.3%
Revenue (ttm)9.23B +134.9%
Net Income-24.19B
EPS-175.00
Shares Out138.13M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume804,410
Average Volume2,253,652
Open3,760.00
Previous Close3,750.00
Day's Range3,750.00 - 3,890.00
52-Week Range1,873.00 - 5,400.00
Beta0.11
RSI51.56
Earnings DateMar 20, 2026

About SillaJen

SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 57
Stock Exchange KOSDAQ
Ticker Symbol 215600
Full Company Profile

Financial Performance

In 2025, SillaJen's revenue was 9.23 billion, an increase of 134.94% compared to the previous year's 3.93 billion. Losses were -24.19 billion, -8.81% less than in 2024.

Financial Statements